MCM2 and meningioma: In this study, we investigated whether the immuno-expression of ACADL and MCM2, used as surrogates of molecular groups MGM3 and MGM4, is associated with reduced RFS or with clinical, pathological and genetic features in a cohort of 55 atypical meningiomas treated with surgery and no radiotherapy.